Pfizer 2014 Annual Report Download - page 6

Download and view the complete annual report

Please find page 6 of the 2014 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 75

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75

PFIZER ANNUAL REVIEW 2014 www.pzer.com/annual 6
ANNUAL REVIEW 2014
PROTECTING ADOLESCENTS AND
YOUNG ADULTS FROM MENINGITIS B
“Meningococcal meningitis B is a devastating
disease, which, though rare, significantly impacts
affected individuals and families. Vaccines have
been available and recommended since 2005
to help protect against four other serogroups
of meningococcal disease, and we hope that
Trumenba will become a recommended vaccine
in routine adolescent immunization programs to
help prevent meningococcal B disease.”
FRANKIE MILLEY
FOUNDER/NATIONAL EXECUTIVE DIRECTOR
MENINGITIS ANGELS
and mother to an only child who died from meningitis
Trumenba (meningococcal group B vaccine) is the rst FDA-approved
vaccine for active immunization to prevent invasive disease caused
by Neisseria meningitidis serogroup B in individuals 10 through 25
years of age. Trumenba was reviewed and approved under the FDA’s
Breakthrough Therapy designation and Priority Review programs.
The unmet medical need was great. This disease is characterized
by high fatality rates and rapid onset, often within 24 hours. For
individuals 11–24 years of age, approximately 30 percent of
meningococcal disease is serogroup B in the U.S., and 10 percent
of these cases result in death.1 As many as 60 percent of adolescent
survivors of meningococcal disease, 15–19 years of age, suffer
from permanent life-altering consequences such as hearing loss,
neurologic damage, or loss of a limb.2 Between the years 2010 and
2012, the estimated average number of annual serogroup B cases in
11- through 24-year-olds was 48–56 cases in the U.S.3
1 Centers for Disease Control and Prevention. Prevention and Control of Meningococcal
Disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep. 2013 March 22; 62(RR02); 1–28. http://www.cdc.gov/mmwr/
preview/mmwrhtml/rr6202a1.htm. Last updated March 22, 2013.
Accessed November 17, 2014.
2 Borg J, Christie D, Coen PG, Pooy R, Viner RM. Outcomes of Meningococcal Disease in
Adolescence: prospective, matched-cohort study. Pediatrics. 2009; 123: e502–e509.
3 MacNeil J. Epidemiology of Serogroup B Meningococcal Disease, United States. Advisory
Committee on Immunization Practices, October 30, 2014. http://www.cdc.gov/vaccines/
acip/meetings/downloads/slides-2014-10/mening-02-MacNeil.pdf.
TRUMENBA® APPROVED AND
AVAILABLE TO PREVENT MENINGITIS B
DISCOVERIES FOR HEALTHIER LIVES
Homepage > Discoveries for Healthier Lives